Australian structural heart company Anteris Technologies Ltd (ASX: AVR) (OTC: ANTTY) announced on Monday a significant milestone as its DurAVR THV, a unique balloon-expandable, single-piece transcatheter aortic valve, demonstrated exceptional results in a second Valve-in-Valve (ViV) procedure conducted under Health Canada's Special Access Program (SAP).

This achievement showcases the promise of the new biomimetic heart valve in addressing life-threatening conditions for patients with failing bioprosthetic aortic valves due to calcification or structural deterioration.

The successful implantation of DurAVR THV in a 79-year-old patient who had previously received a Trifecta surgical valve yielded impressive intraoperative outcomes, including a mean pressure gradient of 7mmHg and restoration of near-normal physiology. With swift patient recovery, the procedure exemplifies the potential for minimally invasive treatments in high-risk cases.

DurAVR THV is actively undergoing investigation through Early Feasibility Studies (EFS) in the US and Europe, focusing on severe aortic stenosis patients. These clinical trials, ClinicalTrials.gov NCT05712161 and Clinicaltrials.gov NCT05182307 respectively, further contribute to the accumulating evidence of the valve's efficacy.

Anteris Technologies Ltd has a strong presence in Minneapolis, US and is dedicated to pioneering innovative medical devices. The company's focus on addressing structural heart diseases with cutting-edge solutions, such as DurAVR THV and the ComASUR Delivery System, positions it as a key player in transforming the treatment landscape for patients in need.